Recently, DOJ announced  that pharmaceutical giant Pfizer, on behalf of its subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”), has agreed to pay nearly $60 million to resolve allegations that Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to health care providers (“HCPs”) to induce prescriptions of Biohaven’s migraine drug Nurtec ODT before Pfizer acquired the company. The set